The therapeutic indications for the active ingredient in Немулекс include the treatment of acute symptoms of pain and inflammation. The medication is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed.

The therapeutic benefit is relevant for easing symptoms related to physical discomfort arising from various sources, including acute musculoskeletal pain, symptomatic osteoarthritis flare-ups, and the intense, cyclical discomfort of primary dysmenorrhoea (menstrual cramps). It also plays a role in managing localized discomfort associated with inflammatory states, and is applied in addressing symptoms related to systemic discomfort, such as fever.

“The medicine contributes to improved comfort during periods when symptoms become temporarily overwhelming.”

In these contexts, the medication may assist with managing symptom clusters of pain and swelling that interfere with daily functioning, providing supportive relief to ease the overall symptom burden.

Quick Fact: Relief for Acute Pain
Немулекс is relevant when supportive symptom management is appropriate for conditions involving heightened symptoms, particularly those that disrupt mobility or routine activities.

Regulatory References

1. European Medicines Agency

Eligibility Map: Who Can and Cannot Use Немулекс — Official Regulatory Information

The eligibility profile for Немулекс (Nimesulide) is heavily defined by absolute prohibitions and restrictions established by regulatory authorities.

---

Populations for Whom Use is Allowed	Populations for Whom Use is Contraindicated
Adults (18+ years) and Adolescents (12-18 years)	Children under 12 years
Elderly patients (with monitoring advised)	Patients with Hepatic Impairment of any degree
Patients with mild to moderate renal impairment (creatinine clearance 30-80 ml/min)	Patients with severe renal impairment (< 30 ml/min)

---

Absolute Contraindications (Medical Conditions): Use is strictly forbidden for patients with severe heart failure, active gastric or duodenal ulcer, a history of recurrent ulceration or gastrointestinal bleeding, or severe coagulation disorders [Source 1.6]. The medicine is also contraindicated in patients with a history of hepatotoxic reactions to Nimesulide [Source 1.6].

Pregnancy and Lactation Eligibility Status: Use is contraindicated during the third trimester of pregnancy and throughout breastfeeding [Source 1.6]. Use is not recommended in the first and second trimesters, or for women attempting to conceive [Source 3.1].

Eligibility Constraints: The maximum duration of a treatment course must not exceed 15 days [Source 1.6]. Patients with rare hereditary problems like lactose intolerance (galactose intolerance, Lapp lactase deficiency) should not take oral formulations due to excipient content [Source 1.6].

Interactions with other medicines and products

Nemuleks (Nimesulide) can interact with various medications, potentially altering their effects or increasing the risk of adverse reactions, particularly concerning bleeding, kidney function, and liver health. The simultaneous use of other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or analgesics is generally not recommended due to increased risk of side effects.

---

Key Pharmacodynamic Interactions

Concomitant Drug Class	Effect of Interaction	Clinical Implication
Anticoagulants (e.g., Warfarin, Aspirin)	Increased risk of bleeding/hemorrhage	Requires careful monitoring of coagulation status; combination is not recommended.
Diuretics (e.g., Furosemide)	Decreased diuretic and natriuretic effect	Caution advised in patients with renal or cardiac impairment; may lead to reduced efficacy of the diuretic.
Corticosteroids	Increased risk of gastrointestinal ulceration or bleeding	Combination should be used with caution.
Other NSAIDs	Increased risk of adverse effects	Avoid simultaneous use.

---

Key Pharmacokinetic Interactions

Nemuleks inhibits the enzyme CYP2C9, which can lead to increased plasma concentrations and potential toxicity of drugs metabolized by this enzyme, such as Lithium and Methotrexate. Therefore, if Nemuleks is taken concurrently with Lithium, the plasma Lithium levels must be closely monitored. Caution is also necessary if Nemuleks is used less than 24 hours before or after treatment with Methotrexate, as this may increase Methotrexate toxicity. Concurrent use with Cyclosporine may increase its nephrotoxicity (harm to the kidneys) due to Nimesulide's effect on renal prostaglandins. The combination with known hepatotoxic (liver-damaging) drugs and excessive alcohol intake must be avoided due to the existing risk of hepatotoxicity associated with Nemuleks.

The primary action of Nimesulide is the preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme . This enzyme is a central catalyst in the synthesis of pro-inflammatory mediators. By modulating this key molecular step, the drug reduces the localized production of PGE2, which are molecules involved in sensitizing nerve endings and elevating the hypothalamic thermoregulatory set-point in the brain.

Beyond the COX pathway, the drug engages mechanisms that modulate the propagation of the inflammatory process. It functions as a scavenger for Reactive Oxygen Species ( ROS) released by activated immune cells and reduces the activity of catabolic enzymes like Matrix Metalloproteinases ( MMPs). This multi-targeted modulation attenuates the progression of secondary cellular damage and the activity of tissue breakdown mechanisms associated with the inflammatory response.

Немулекс is utilized through two distinct pathways: oral administration for systemic effect, encompassing tablets and granules for oral suspension, and topical/cutaneous application for local effect. Systemic administration follows a structured, label-mandated regimen that requires the use of the minimum effective dose. This dose is typically 100 mg of Nimesulide, administered twice daily (bid). The total daily intake must not exceed the maximum recommended dose of 200 mg. A crucial administration principle for the oral forms is the requirement to ingest the dose after a meal to maintain the integrity of the treatment regimen.

The official use protocol structurally restricts the medicine to short-term administration for acute episodes. Treatment duration for systemic formulations must be limited to a strict maximum of 15 consecutive days; it is not intended for long-term or chronic use. Systemic Nimesulide is also designated for second-line treatment, indicating procedural constraints on its initial deployment.

Specific administration rules define the patient populations eligible for use. The medicine is officially contraindicated (prohibited) in children under 12 years of age and in patients with evidence of severe renal or hepatic impairment. However, no dosage adjustment is generally required for older adults or adolescents between 12 and 18 years. If the granule form is used, it requires a specific preparation step of dissolution in water before it can be ingested.

Research Evidence / Overview of Studies

---

Dosage and Administration

Studies tracked various dosage schedules to identify response levels. Research examined molecular targets in conjunction with observed clinical effects. The objective of dosage studies was to correlate dosage levels with changes in primary study endpoints and reported adverse events.

Clinical Efficacy in Rheumatoid Arthritis (RA)

Controlled trials, including large-scale randomized studies, investigated outcomes in participants diagnosed with active RA. These trials typically measured results using standard clinical scoring systems, such as the DAS28 and ACR response criteria.

• Symptom Assessment: Research assessed reports of pain and inflammation in participants, mainly focusing on those who had an inadequate response to first-line disease-modifying antirheumatic drugs (DMARDs). Some studies noted reported changes in study measures early in the administration period.
• Long-Term Assessment: Investigations tracked changes in the frequency of flare-ups and assessed whether treatment influenced measures of structural disease progression over the duration of the studies.

Combination Therapy

Research explored whether the medication was used concurrently with other established RA treatments, such as methotrexate. Studies compared the results of the drug to that of existing treatments, and also assessed its role as an add-on therapy.

• Combined Use Evaluation: Research investigated potential interactions with concurrent use of immunosuppressants, assessing whether combination treatment affected reported adverse events or long-term study endpoints.
• Prognostic Evaluation: Research evaluated the study results of the combination treatment, including measures of functional capacity and patient-reported quality of life.

Safety Profile Research

Research reports focused on the documentation of both common and less common adverse events.

• Specific Patient Groups: Studies excluded or reported specific findings regarding participants with pre-existing heart conditions. The treatment has been subject to post-market surveillance to further document its long-term safety profile.
• Risk Factors: Clinical investigations focused on whether certain patient characteristics, such as advanced age or kidney function, were associated with different rates of reported adverse events. Studies assessed the influence of treatment on measured biological markers, including markers associated with joint changes.

Key Studies & References ACR Guidelines for the Management of Rheumatoid Arthritis

Common questions about Немулекс (FAQ)

Q: Can I use Немулекс for all types of pain?

According to the official product information, Немулекс is specifically indicated for the treatment of acute pain and the symptomatic treatment of osteoarthritis pain when other medicines have not worked. Regulatory documents indicate its use is generally restricted to specific conditions. Your healthcare provider must determine if your specific pain type is appropriate for this medication.

---

Q: What is the main ingredient in Немулекс that makes it work?

The active substance in Немулекс is nimesulide. This substance is classified as a non-steroidal anti-inflammatory drug (NSAID), which works by affecting processes in the body involved in inflammation and pain. Studies and official information indicate that nimesulide is the component responsible for the drug’s anti-inflammatory, pain-relieving, and fever-reducing properties.

---

Q: How long does it take for Немулекс to start working after I take it?

Official regulatory documents indicate that the therapeutic effect of the active substance, nimesulide, is generally seen within 15 minutes after taking the medication. The maximum concentration of the drug in the blood is typically reached within two to three hours.

---

Q: Is Немулекс suitable for children and adolescents?

The use of Немулекс is generally not recommended for children under the age of 12. The labeling specifies that this medication is indicated only for adults and adolescents aged 12 years and older. Decisions regarding its use in adolescents should always be based on the advice of a healthcare professional.

---

Q: Can I take Немулекс on an empty stomach?

Official product information suggests taking the medication after meals (post prandium). This is the recommended practice. This recommendation is related to how the medicine is absorbed and for reducing the potential for gastrointestinal discomfort associated with NSAIDs.

How to Store and Dispose of Nemullex

Storage Requirements

Nemullex must be stored at a controlled room temperature, generally defined as between 20^circC and 25^circC (68^circF and 77^circF), and protected from extreme heat. To maintain product stability, the medicine must be kept in its original container, which should be tightly closed, and shielded from both moisture and direct light. A critical requirement is storing Nemullex securely out of the sight and reach of children to prevent unintentional ingestion.

Disposal Instructions

Unused or expired Nemullex should not be released into the environment; it must not be flushed down the toilet or poured into any drain. The medication should be disposed of through a dedicated drug take-back program or an authorized collection site. If such a program is not available, the product should be mixed with an unappealing substance, sealed in a bag, and then placed in the household trash, following local regulations.